New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Future Oncology - Technology, Products, Markets, and Service Opportunities

* Requires Adobe Acrobat Reader

FUTURE ONCOLOGY - TECHNOLOGY, PRODUCTS, MARKETS, AND SERVICE OPPORTUNITIES IN THE CANCER FIELD

FUTURE ONCOLOGY
Volume 9 #5/6
December 31, 2007

DRUG DEVELOPMENT IN ONCOLOGY

THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFr) PATHWAY IN CANCER
PART IV - DEVELOPMENTAL INDICATIONS OF COMMERCIALLY AVAILABLE ErbB PATHWAY INHIBITORS

DEVELOPMENTAL INDICATIONS OF APPROVED ErbB PATHWAY INHIBITORS

BREAST CANCER

  • Advanced or Metastatic Breast Cancer
    • Trastuzumab
    • Lapatinib
    • Erlotinib
    • Cextuximab
    • Gefitinib
  • Triple Receptor Negative Breast Cancer
  • Breast Cancer Metastasized to the Brain
    • Trastuzumab
    • Lapatinib
  • Inflammatory Breast Cancer
    • Lapatinib
    • Trastuzumab
  • Adjuvant/Neoadjuvant/Early-Stage Treatment
    • Trastuzumab
    • Lapatinib
    • Erlotinib
  • Approved ErbB Pathway Inhibitors in Combination with Hormonal Therapy
  • Approved ErbB Pahtway Inhibitors in Combination with Other Approved ErbB Inhibitors
  • Approved ErbB Pathway Inhibitors in Combination with Other Approved Targeted Agents
    • Bevacizumab
    • Everolimus

LUNG CANCER

  • Advanced or Metastatic NSCLC
    • Erlotinib
    • Cetuximab
    • Gefitinib
    • Nimotuzumab
  • Bronchoalveolar Carcinoma (BAC)
  • Early Stage Nonmetastatic NSCLC

COLORECTAL CANCER

  • Advanced or Metastatic Colorectal Cancer
    • Cetuximab
    • Panitumumab
    • Nimotuzumab
  • Colorectal Cancer Metastasized to the Liver
  • Adjuvant/Neoadjuvant Treatment for Early Stage Colorectal Cancer

OTHER MALIGNANCIES

  • Head and Neck Cancer
    • Cetuximab
    • Panitumumab
    • Erlotinib
    • Gefitinib
    • Lapatinib
  • Pancreatic Cancer
    • Erlotinib
    • Nimotuzumab
  • Primary Brain Cancer
  • Primary Liver Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • Ovarian Cancer
  • Bladder Cancer
  • Mesothelioma

MARKET UPDATE


LIST OF EXHIBITS

Exhibit 1 - Combination Trials of ErbB Inhibitors and Hormone Modulators in Breast Cancer

Exhibit 2 - Ongoing Clinical Trials in Breast Cancer Combining Bevacizumab and Trastuzumab

Exhibit 3 - Global Sales of ErbB-pathway Targeted Agents in the First Nine Months of 2007


HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887